Pharmacologic and global gene deletion studies demonstrate that cyclooxygenase-2 (PTGS2/COX-2) plays a critical role in DMBA/TPA-induced skin tumor induction. Although many cell types in the tumor microenvironment express COX-2, the cell types in which COX-2 expression is required for tumor promotion are not clearly established. Here, cell type-specific Cox-2 gene deletion reveals a vital role for skin epithelial cell COX-2 expression in DMBA/TPA tumor induction. In contrast, myeloid Cox-2 gene deletion has no effect on DMBA/TPA tumorigenesis. The infrequent, small tumors that develop on mice with an epithelial cell-specific Cox-2 gene deletion have decreased proliferation and increased cell differentiation properties. Blood vessel density is reduced in tumors with an epithelial cell-specific Cox-2 gene deletion, compared with littermate control tumors, suggesting a reciprocal relationship in tumor progression between COX-2-expressing tumor epithelial cells and microenvironment endothelial cells. Lipidomics analysis of skin and tumors from DMBA/TPA-treated mice suggests that the prostaglandins PGE 2 and PGF 2a are likely candidates for the epithelial cell COX-2-dependent eicosanoids that mediate tumor progression. This study both illustrates the value of cell type-specific gene deletions in understanding the cellular roles of signal-generating pathways in complex microenvironments and emphasizes the benefit of a systems-based lipidomic analysis approach to identify candidate lipid mediators of biologic responses.
Introduction
Over 3 million nonmelanoma skin cancers occur annually in the United States (1) . Ease of monitoring has made mouse skin cancer a popular model to study cancer development (2) . The most commonly used model is the "two stage" 7,12 dimethylbenz[a]anthracene (DMBA) "initiation"/12-0-tetradecanoylphorbol-13-acetate (TPA) "promotion" paradigm, resulting in papillomas "consisting of hyperplastic keratinocytes and supporting stroma" (3) . A percentage of papillomas "progress" to squamous cell carcinomas (SCC). "Initiation" results from c-H-Ras mutations in skin epithelial cells (3, 4) ; "promotion" is the TPA-driven clonal expansion of initiated keratinocytes to benign papilloma formation; "progression" is papilloma growth and conversion to SCCs (3, 5) . Skin papillomas and SCCs can also be induced by repeated UVB-irradiation of SKH-1 hairless mice (6) .
Prostaglandins (PG) are derived from arachidonic acid. Arachidonate, released from plasma membrane phospholipids by phospholipases, is converted to PGH 2 by cyclooxygenase (COX) enzymes. PGH 2 is subsequently converted to prostanoids (e.g., PGE 2 , PGD 2 , and PGI 2 ) by alternative prostanoid synthases (7) . There are two Cox genes (8) , Cox-1 and Cox-2 (7). Both COX-1 and COX-2 are inhibited by nonsteroidal anti-inflammatory drugs (NSAID; e.g., aspirin and indomethacin). COX-2 discovery prompted a search for selective inhibitors to reduce COX-1 inhibition adverse effects (e.g., gastric irritability and blood clotting inhibition), culminating in development of Coxibs (COX-2 selective inhibitors; e.g., Celebrex; ref. 7 ).
1 COX-2 is overexpressed in many epithelial cancers (9, 10) . COX-2 expression is essential for DMBA/TPA skin tumor induction; NSAID or Coxib treatment reduces tumor incidence and frequency (11) . Global Cox-2 gene deletion similarly reduces DMBA/TPA-induced tumors (12) . UVB-induced skin cancer is also blocked by COX-2 inhibition (13) and by Cox-2 deletion (14, 15) .
Epithelial tumor cells live in a cellular microenvironment that includes fibroblasts, vasculature cells (e.g., endothelial cells, smooth muscle cells, and pericytes), and immune cells (e.g., macrophages, lymphocytes, and mast cells). The role of the "tumor microenvironment" in epithelial cancer development is a major topic in cancer research (16) (17) (18) . COX-2 overproduction following DMBA/TPA treatment is reported in a variety of cell types, leading to the suggestion that COX-2 production in stromal/microenvironment cells modulates tumor progression (19) . However, neither COX-2 inhibition nor Cox-2 deletion can identify cell type(s) in which COX-2 expression is necessary for skin cancer development; both reduce COX-2 function in all cells. To determine COX-2 cell-specific roles, we developed Cox-2 flox/flox mice (20) , in which Cox-2 can be deleted with cell type-specific Cre recombinase expression. Here, we use Cox-2 flox/flox mice to determine the roles of skin keratinocyte-and myeloid cellspecific COX-2 expression in DMBA/TPA-induced skin tumorigenesis.
Materials and Methods

Animals
Cox-2 flox/flox (Cox-2 fl/fl ), Cox-2 flox/flox ;K14Cre þ (Cox-2
DE
), and Cox-2 flox/flox ;LysMCre þ (Cox-2 DM ) mice, breeding, and genotyping were described previously (20, 21) . Animal experiments were performed with approval by the University of California, Los Angeles (UCLA; Los Angeles, CA) Institutional Animal Care and Use Committee (IACUC).
DMBA/TPA treatment
This procedure was described previously (22, 23) . Briefly, female mice were initiated with a single application of 50 mg of DMBA (Sigma). Two weeks after initiation, all groups received twice-weekly applications of 5 mg of TPA until the experiment was terminated. Tumor incidence (percentage mice with tumors) and tumor multiplicity (papillomas/ mouse) were determined weekly. Tumor incidence and multiplicity differences were analyzed by x 2 tests and Mann-Whitney U test, respectively.
Immunohistochemistry analyses
Skin and papilloma sections were fixed (4% paraformaldehyde), paraffin-embedded, sectioned (4 mm), and stained with hematoxylin and eosin (H&E) or processed for immunohistochemistry. Antigen retrieval was done by heating (95 C in citrate buffer, pH 6.0) or Proteinase K (Dako) treatment (37 C). Antibodies are described in Supplementary Table S1 . Samples were visualized with a NIKON Eclipse TE 2000-U microscope.
Epidermal thickness
Epidermal thickness (distance between basement lamina and apical surfaces of uppermost nucleated keratinocytes; ref. 24) was measured on H&E sections. Measurements and quantification were performed with NIS-Elements BR 3.00 software (Nikon).
Quantification of immunohistochemical staining
Skin. Skin proliferation index: Ki67-positive basal cells/ total basal cells. Premature basal cell differentiation index: Keratin 1 (K1)-positive basal cells/total basal keratinocytes.
Tumors. Morphometric analysis was performed with Definiens' Tissue Studio (Definiens Inc.), using ScanScope AT instrumentation. Ki67-positive cells were determined with the predefined nuclear detection module and classification tool; positive and negative nuclei within each epithelial region were identified. Thresholds were set to classify hematoxylin stain for negative nuclei and DAB stain for positive nuclei. K1-positive epithelial cells/total epithelial cells and F4/80-positive macrophages/unit area were identified and quantified using the predefined cytoplasm detection module and classification tool. Blood vessel densities (vessels/unit area), based on CD31-positive staining, were determined with the predefined vessel detection module and classification tool. Data were analyzed using an unpaired Student t test.
Eicosanoid profiling
Papillomas and skin samples were weighed, snap-frozen in liquid nitrogen, and stored at À80 C. Sample extraction and mass spectrometry were previously reported (25) . An additional homogenization, using an Ultra-Turrax T25 Homogenizer (Fisher Scientific), was used before solid-phase extraction. Samples thawed on ice were homogenized.
Results
Epidermal keratinocyte Cox-2 deletion reduces DMBA/ TPA skin tumor induction
We observe COX-2 expression in DMBA/TPA-induced Cox-2 fl/fl mice papillomas, and find macrophages present in these tumors (Fig. 1A) . To examine the cell-specific role of keratinocyte COX-2 expression in DMBA/TPA skin cancer induction, we compared tumor induction in Cox-2 DE mice (in which Cox-2 is deleted in keratinocytes; Supplementary  Fig. S1 ) to tumor induction in Cox-2 fl/fl littermates. Epithelial Cox-2 deletion significantly decreased tumor incidence in Cox-2 DE mice; 59% of Cox-2 DE mice developed papillomas. In contrast, 93% of Cox-2 fl/fl mice developed papillomas ( Fig. 1B; x 2 test, P < 0.05). Moreover, DMBA/ TPA-induced papilloma multiplicity was reduced by nearly 80% in mice unable to express COX-2 in keratinocytes, when compared with Cox-2 fl/fl mice (Fig. 1B , Mann-Whitney U test, P < 0.05-0.001, week [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Skin tumors that did develop on Cox-2 DE mice were much smaller than tumors on Cox-2 fl/fl mice ( Fig. 2A) . Loss of one Cox-2 allele reduces, but does not eliminate, DMBA/TPA skin tumor induction (12) . If incomplete Cre recombinase cleavage of floxed Cox-2 alleles in Cox-2 DE mice occurs, these mice might develop heterozygous, COX-2-expressing tumors. Consequently, we analyzed COX-2 expression in papillomas from DMBA/TPA-treated Cox-2 fl/fl and Cox-2 DE mice. As expected, epithelial cells in papillomas from DMBA/TPA-treated Cox-2 fl/fl mice express COX-2 protein (Fig. 2B) . In contrast, COX-2 expression was undetectable in epithelial cells of papillomas from Cox-2 DE mice (Fig. 2B ). These data demonstrate that DMBA/TPA-induced tumors present on Cox-2 DE mice are not COX-2 expression "escapees."
Myeloid cell Cox-2 deletion has no effect on DMBA/TPA tumor induction
To investigate the role of myeloid cell COX-2 in DMBA/TPA-induced skin cancer, we compared tumor induction in treatment, skin of Cox-2 DE mice exhibits significantly reduced hyperplasia (i.e., epidermal thickness) when compared with skin of similarly treated Cox-2 fl/fl mice (Fig. 3A) . A short 2-week TPA treatment following DMBA initiation also led to decreased epidermal hyperplasia in Cox-2 DE mice ( Supplementary Fig. S3A ). No skin papillomas are present at this time (Fig. 1B) . In contrast to reduced hyperplasia in Cox-2 DE mice (Fig. 3A) , skin of Cox-2 DM mice and Cox-2
littermates undergo similar degrees of DMBA/TPAinduced hyperplasia (Fig. 3B ).
Epidermal keratinocyte-specific Cox-2 deletion does not affect DMBA/TPA-induced epidermal cell proliferation, but induces aberrant epidermal differentiation As basal cells move to suprabasal locations, they cease proliferation and undergo terminal differentiation. The balance between keratinocyte proliferation and differentiation is critical to maintain epidermal homeostasis (26) . To investigate whether the reduced skin hyperplasia of Cox-2 DE mice following chronic, repeated TPA treatment (Fig. 3A) may result from decreased keratinocyte proliferation, the Ki67 marker for proliferating cells was examined in skin from untreated mice and mice were treated for 20 4B ). K1 is expressed in keratinocytes as they commit to differentiation (27) . Untreated skin from mice with a keratinocyte-specific Cox-2 deletion and their Cox-2 fl/fl littermates have similar low K1 antigen expression levels in suprabasal epidermal cells (Fig. 4C ). Global Cox-2 deletion results in premature differentiation in epidermal basal cells after DMBA/TPA treatment, when compared with
mice shows a greater than 3-fold increase in K1-positive basal cells relative to skin of DMBA/TPA-treated Cox-2 fl/fl littermates ( Fig. 4C and D) ; the basal cell population undergoes premature terminal differentiation in Cox-2 DE mice but not in Cox-2 fl/fl littermates. In addition to proliferation and differentiation, apoptosis can potentially contribute to epidermal homeostasis (28) . However, apoptosis was minimal in skin from both untreated Cox-2 DE and Cox-2 fl/fl mice, and was not substantially increased in skin from DMBA/TPA-treated mice of either strain ( Supplementary Fig. S4 ).
DMBA/TPA-induced papillomas of Cox-2 DE mice have a decreased proliferation index
The increase in proliferation of skin epidermal cells in response to DMBA/TPA treatment is similar in Cox-2 DE and Cox-2 fl/fl littermates (Fig. 4B ). However, papillomas on DMBA/TPA-treated Cox-2 DE mice are smaller than those on their Cox-2 fl/fl littermates ( Fig. 2A ). These observations raised the question of whether, unlike in skin, proliferation indices of papillomas present on Cox-2 DE mice are reduced relative to proliferation indices of papillomas present on Cox-2 fl/fl littermates. Ki67 proliferation indices for DMBA/ TPA-induced Cox-2 DE papillomas were 2-fold lower than proliferation rates of Cox-2 fl/fl littermate papillomas (Fig.  5A ). The data suggest that, once initial promotion event(s) for DMBA/TPA-induced papillomas occur in skin of Cox-2 DE mice, proliferation may become a rate-limiting step in tumor progression. In contrast, myeloid cell Cox-2 deletion had no discernible effect on tumor cell proliferation in DMBA/TPA-induced papillomas (Fig. 5A ).
Epithelial cells of DMBA/TPA-induced papillomas from
Cox-2 DE mice exhibit increased differentiation Loss of cell differentiation is generally associated with cancer progression; reduced K1 expression is associated with DMBA/TPA-induced skin progression (5). Conversely, induced tumor cell differentiation is thought to retard cancer progression (29) (30) (31) (32) . Premature basal cell differentiation in DMBA/TPA-treated mouse skin, previously demonstrated to be a property of mice with a global Cox-2 deletion (12), is an intrinsic property of the epidermal tumor precursor cell, occurring in Cox-2 DE mice ( Fig. 4C and D) . These data suggest that a tendency to premature differentiation, as a result of loss of intrinsic epithelial cell COX-2 expression, 5B) . In contrast, myeloid Cox-2 deletion in Cox-2 DM mice had no detectable effect on epithelial tumor cell differentiation (Fig. 5B ).
An increase in apoptosis of epithelial tumor cells in the DMBA/TPA-induced papillomas on Cox-2 DE mice, relative to apoptosis in tumors on Cox-2 fl/fl mice, could also contribute to the reduced tumor progression observed in Cox-2 DE mice. However, apoptotic cells were very sparse both in tumors of Cox-2 DE mice and their Cox-2 fl/fl littermates ( Supplementary Fig. S4 ), and quantifiable differences could not be demonstrated.
Eicosanoid profiles of skin and skin tumors from DMBA/ TPA-treated Cox-2 DE mice, Cox-2 DM mice, and their Cox-2 fl/fl littermates DMBA/TPA-induced skin tumors have within them epithelial cells, macrophages, endothelial cells, fibroblasts, and other stromal and immune cells. The targeted Cox-2 deletions described here eliminate one of the two cyclooxygenases, COX-2, in single cell types (epithelial keratinocytes or myeloid cells) of the tumors. By analyzing total tumor eicosanoid profiles, one can determine whether the absence of COX-2 only in epithelial tumor cells, or only in myeloid cells, will alter significantly polyunsaturated fatty acid metabolism in DMBA/TPA-induced skin cancer; that is, measuring total eicosanoids will allow us to address the question "to what extent does either keratinocyte-specific COX-2 or myeloid-specific COX-2 contribute to eicosanoid metabolism in DMBA/TPA-induced skin tumors?"
We developed a comprehensive lipidomic approach for complete extraction of tissue eicosanoids, combined with high-throughput LC/MS-MS methodology to quantify multiple eicosanoid species (25) . We collected, from all four groups of mice (Cox-2 DE and their Cox-2 fl/fl littermates, and Cox-2 DM and their Cox-2 fl/fl littermates), (i) untreated skin, (ii) DMBA/TPA-treated skin, and (iii) papillomas from DMBA/TPA-treated mice. Eicosanoid extracts were analyzed by high-throughput mass spectrometry, using multiple reaction monitoring scanning (25) . Despite profound differences in tumor incidence, frequency, and size for tumors of Cox-2 DE mice when compared with tumors of their Cox-2 fl/fl littermates (Figs. 1B and 2A), no statistically significant differences in total eicosanoid amounts present in tumors from these mice was detectable (Fig. 6A) . Similarly, there is no detectably significant difference in total eicosanoid content in DMBA/TPA-induced skin tumors from Cox-2 DM mice and their Cox-2 fl/fl littermates (Fig. 6A) .
Complete lipidomic analysis allows comparison of COXdependent product levels, nonenzymatic eicosanoids, lipoxygenase-dependent products (LOX), and cytochrome P450 products (CYP) in the tumor sets. LOX products, which constitute the majority of tumor eicosanoid metabolites (Fig.  6B) , do not differ in total mass when comparisons are made between tumors from experimental and littermate control mice; no statistically significant differences were detected. However, although the amounts of COX-dependent eicosanoids is perhaps surprisingly low, a small but statistically significant reduction in total COX-dependent eicosanoids (Fig. 6B) . In contrast, myeloid cell Cox-2 deletion had no effect on total COXdependent eicosanoids in DMBA/TPA-induced tumors (Fig. 6B) .
The decrease in COX-dependent eicosanoids in Cox-2 DE mice ( Fig. 6B) suggests that an epithelial-specific COX-2-dependent product(s), absent in tumors of these mice but present in tumors of their Cox-2 fl/fl littermates, may be responsible for the differences in tumor number and progression observed in Cox-2 DE mice and their Cox-2 fl/fl littermates (Figs. 1B and Fig. 2A ). COX products whose levels are reduced in Cox-2 DE tumors, but not in tumors of the other mouse genotypes, are likely to include candidates for the keratinocyte-specific COX-2 product(s) that drives DMBA/TPA-induced tumors. A "heatmap" (Fig. 6C) , identifies those COX-dependent products that are significantly reduced in tumors of Cox-2 DE mice versus their Cox-2 fl/fl littermates, and compares these data with the (lack of) changes in levels of these same eicosanoids in Cox-2 DM mice and their Cox-2 fl/fl littermates. To identify COX-2-dependent prostanoids that are likely candidates as causal drivers in COX-2-dependent DMBA/ TPA tumor proliferation/progression, we compared levels of the COX-2-dependent eicosanoids reduced in papillomas from Cox-2 DE mice relative to their Cox-2 fl/fl littermates ( Fig.  6C ) with the levels of those same eicosanoids in skin samples from the same DMBA/TPA-treated mice. Our hypothesis was that epithelial-cell COX-2-dependent prostanoids causal for tumor progression would be decreased in tumors from Cox-2 DE mice relative to their Cox-2 fl/fl littermates; that the keratinocyte COX-2-dependent eicosanoids that drive tumor progression would (i) be elevated in tumors from Cox-2 fl/fl mice and (ii) be reduced, in tumors in Cox-2 DE mice, to levels similar to skin samples from these mice. As additional supporting evidence, we proposed that the presumptive epithelial cell COX-2-dependent eicosanoids that drive DMBA/TPA tumor progression would be elevated in DMBA/TPA-induced tumors from both Cox-2 DM mice and their Cox-2 fl/fl littermates, relative to these eicosanoids in skin from Cox-2 DE mice. The two COX-2-dependent eicosanoids that meet the above criteria are PGE 2 and PGF 2a (Fig. 6D) . For both PGE 2 (Fig. 6D) . Either (or both) of these intrinsic keratinocyte COX-2-dependent eicosanoids is/are likely to be a major driver(s) of DMBA/TPA-induced tumor promotion/progression. Although we observe statistically significant differences in nonenzymatically derived eicosanoids and CYP-derived eicosanoids, functional significance of these eicosanoids to DMBA/TPA-induced tumorigenesis is not clear. There were no detectable differences in PGE 2 and PGF 2a levels in DMBA/TPA-treated skin of Cox-2 DE and their Cox-2 fl/fl littermates, although-in both cohorts-repeated TPA treatment did substantially increase levels of the two eicosanoids when compared with untreated skin (Fig. 6D) . Additional COX-2 IHC studies suggested that, while a single TPA application to mouse skin significantly increased epithelial COX-2 levels, long-term repeated TPA treatment does not lead to elevated COX-2 expression in the skin ( Supplementary Fig. S5 ), as previously reported by MullerDecker and colleagues (33) . However, papillomas from the same mouse show elevated COX-2 expression relative to adjacent skin.
DMBA/TPA-induced papillomas of Cox-2 DE mice exhibit reduced vascularity
The most parsimonious explanation for reduced DMBA/ TPA skin tumor induction in Cox-2 DE mice is that the critical epithelial cell COX-2-dependent prostanoids act intrinsically on the same cell that produces them. In the absence of these epithelial cell-specific, COX-2-dependent prostanoids and their intrinsic autocrine modulatory effect on the initiated epithelial cell, proliferation is decreased and differentiation is increased, resulting in reduced tumor progression. However, it is also possible, and even likely, that COX-2-dependent prostanoids secreted by DMBA/TPAinduced tumor cells act on other cells in the tumor microenvironment. As a consequence, these cells modulate proliferation, differentiation, and additional properties of the epithelial tumor cells in a reciprocal relationship that modifies tumor promotion/progression. Among the cells in the tumor microenvironment thought to modulate tumor proliferation/progression are infiltrating macrophages and endothelial cells for blood vessel formation (34, 35) . To investigate possible epithelial cell-specific COX-2-dependent prostanoid modulation of extrinsic cells in the tumor microenvironment, we evaluated (i) macrophage migration into tumors of Cox-2 DE mice and their Cox-2 fl/fl littermates and into tumors of Cox-2 DM mice and their Cox-2 fl/fl littermates, and (ii) tumor blood vessel densities in these 4 mice cohorts.
Macrophage infiltration was evaluated by quantitative F4/80 þ cell density determination in tumors (Fig. 7A ). Despite differences in tumor incidence, multiplicity, and size, macrophage densities in tumors from Cox-2 DE and Cox-2 fl/fl littermates were not significantly different (Fig. 7A) . Moreover, macrophage densities in Cox-2 DM mice and keratinocyte-specific, COX-2-dependent prostanoid production modulates blood vessel density in DMBA/TPAinduced tumors. Moreover, the papillomas derived from Cox-2 DE mice have an increased percentage of small vessels and a correspondingly decreased percentage of (mediumsize þ large-size) vessels, when compared with vessels formed in tumors of Cox-2 fl/fl mice ( Supplementary Fig.  S6 ). In contrast, no significant difference in blood vessel density or size distribution was observable in tumors from Cox-2 DM and Cox-2 fl/fl littermate mice ( Fig. 7B and Supplementary Fig. S6 ).
Discussion
COX-2 overexpression occurs in many epithelial tumors and is suggested to play a modulatory role in many cancers. However, COX-2 expression occurs in tumor epithelial cells and also in other cell types within the tumor microenvironment. Although COX-2 inhibitor and global Cox-2 deletion studies provide unequivocal evidence that COX-2 plays a major role in driving DMBA/TPA-induced mouse skin cancer, one cannot determine the causal effects of COX-2-dependent prostanoids from different cell types either by pharmacologic or by global gene knockout approaches; both procedures eliminate COX-2 activity in all cell types. Here, using cell type-specific Cox-2 deletion, we demonstrate a requirement for intrinsic epithelial keratinocyte COX-2 expression in DMBA/TPA-induced skin cancer progression. In addition, we demonstrate that myeloid COX-2 expression has no significant role in DMBA/TPA-induced skin cancer development.
To address the role of epithelial cell COX-2 in skin cancer formation, we ablated the Cox-2 gene using mice expressing K14-Cre. K14 is expressed in skin by E14.5 (36) . K14-Cre is expressed in progenitor cells in the basal layer and hair follicular bulge stem cells (36) and can successfully label skin cancer stem cells, using a genetic lineage tracing system (37) . Consequently, skin epithelial cells and their precursors in Cox-2 DE mice will be deleted for COX-2 expression, as will the tumor cells derived from cancer stem cells.
Lao and colleagues (38) approached the role of autonomous COX-2 expression for Ras-initiated epithelial cells in tumorigenesis in a different manner; they transformed Cox-2 þ/þ and Cox-2 À/À keratinocytes with a v-H-Ras retrovirus and analyzed the ability of the transformed cells to form tumors following cutaneous orthografting onto athymic, immunodeficient mice. After 4 weeks, tumor incidence was reduced approximately 25% and tumor size was reduced approximately 60% for Cox-2 À/À Ras-transformed keratinocyte orthografts. Their data, like our own, support the conclusion that intrinsic COX-2 expression in skin epithelial cells bearing an oncogenic Ras gene plays a major role in driving skin tumor promotion. However, tumor formation in their experiment is really "one stage"; the v-H-Ras- þ/þ counterparts, suggesting that tumor cell-autonomous COX-2 expression plays an important role in modulating these skin tumor characteristics. The most parsimonious explanation for these results is that COX-2-dependent prostanoids produced by epithelial tumor cells play a cell-autonomous role in driving tumor cell proliferation and retarding tumor cell differentiation. However, Lao and colleagues (38) find no difference in tumor vascularization in v-H-Ras;Cox-2 þ/þ and v-H-Ras;Cox-2 À/À keratinocyte-derived tumors (38) , while we find a 2-fold difference in tumor vascularization between DMBA/TPA-induced tumors present on Cox-2 DE mice and their Cox-2 fl/fl littermates (Fig. 7B ). Our data suggest (i) that skin epithelial tumor cell COX-2-dependent prostanoids may also modulate biologic properties of other cell types in their microenvironment and (ii) that, as a consequence, cells of the microenvironment may then reciprocally respond to tumor cell COX-2-dependent prostanoids to subsequently modulate tumor development.
Additional differences between the Lao and colleagues study (38) and our own that may influence tumor formation are (i) the number of initiated cells from which tumors arise; Lao and colleagues (38) engraft 3 Â 10 6 v-H-Ras-transformed keratinocytes at a single site, while tumors in our experiment likely develop from individual Ras-initiated cells, (ii) differences in the biology of keratinocytes transformed by v-H-Ras retrovirus in culture and mutated c-H-Ras-initiated cells, and (iii) lack of an immune system in the engrafted athymic immunodeficient mouse for what is thought to be an inflammation-driven process. In addition, we note differences in time to detectable tumor formation; less than 2 weeks for Lao and colleagues (38) versus 6 to 8 weeks for DMBA/TPA-induced tumors (22, 23) .
The most direct reconciliation of the Lao and colleagues data (38) and our own suggest that v-H-Ras-transformed keratinocytes, capable of rapidly forming tumors in the absence of promotion but dependent on COX-2 expression (38), may reflect skin keratinocytes from DMBA/TPAtreated mice that have transitioned to intrinsic COX-2 dependence in the two-stage carcinogenesis model. Both experiments do converge on the requirement for intrinsic COX-2 expression in skin epithelial cells for robust tumor formation.
We observe an approximately 10-fold increase in PGE 2 and PGF 2a (Fig. 6D) controls. The data suggest that the elevated prostanoid levels observed in DMBA/TPA chronically-treated skin are not dependent on keratinocyte COX-2 production. In contrast, global Cox-1 deletion, which also greatly reduces DMBA/ TPA skin tumor induction, significantly reduces skin PGE 2 levels in DMBA/TPA-treated mice (12) . These data suggest (i) that COX-1 expression in skin of DMBA/TPA-treated mice is likely to play a role in TPA-driven progression of DMBA-initiated cells to papillomas and (ii) that elevated COX-2 expression in initiated keratinocytes is necessary, at some point(s), for transition to a detectable papilloma. Like Muller-Decker and colleagues (33), we observe COX-2 expression in papillomas of DMBA/TPA-treated mice, but not in adjacent skin (Supplementary Fig. S5 ). Moreover, using heterozygous mice in which a luciferase reporter is substituted for the coding region of the Cox-2 gene in one allele, elevated luciferase expression is detectable as soon as a visible DMBA/TPA-induced papilloma is present, but not before this point (22) . These data suggest that an elevated COX-2 expression in skin epithelial cells is required at, and subsequent to, this point in time for DMBA/TPA-driven papilloma appearance and progression, but may not be required before this point for subsequent tumor production. There appears to be a TPA-induced, but epithelial/keratinocyte COX-2-independent event(s) that occurs in DMBA-initiated skin. However, TPA-dependent, increased epithelial cell COX-2 expression is required for DMBA/TPA tumor induction. The data suggest that, in skin of DMBA/TPA-treated mice, epithelial cells may undergo a "preprogression" event (or events) that is (are) not dependent on epithelial keratinocyte COX-2 prostanoid production. Once this preprogression event(s) is completed, the cells become committed to a transition to papilloma formation; this transition requires increased COX-2 production in the initiated skin epithelial cell.
Tumor promotion is stunted in the absence of an increase in COX-2 expression in initiated epithelial cells; COX-2 elevation in DMBA/TPA-treated epithelial cells is required for sustained tumor promotion. The smaller, less frequent tumors observed on DMBA/TPA-treated Cox-2 DE mice ( Figs. 1 and 2 ) may reflect the beginning, but relatively unsuccessful, proposed epithelial cell COX-2-dependent transition.
Identification of prostanoids that mediate DMBA/TPAinduced skin tumor progression has been primarily of the "candidate prostanoid" approach (12) . PGE 2 (40) and PGF 2a (41) have emerged as the prostaglandins thought to modulate DMBA/TPA-induced skin cancer. Our unbiased analysis of arachidonic acid metabolites present in untreated skin, DMBA/TPA-treated skin, and DMBA/TPA-induced papillomas of Cox-2 DE and Cox-2 fl/fl mice demonstrates that PGE 2 and PGF 2a are, indeed, the strongest candidates for transformed epithelial cell COX-2-derived prostaglandins that drive DMBA/TPA skin cancer; PGE 2 and PGF 2a levels of the less frequent, smaller papillomas of Cox-2 DE mice are substantially lower than those of papillomas on Cox-2 skin. Interestingly, PGF 2a , but not PGE 2 , can reverse the inhibition of Indomethacin for DMBA/TPA skin tumor induction (33) .
We suggest it is only by targeted, cell type-specific deletion of COX-2 expression and targeted cell type-specific deletion of appropriate prostaglandin receptors that the complex network of tumor cell autonomous and extrinsic cell COX-2-dependent prostanoid signaling in skin tumor progression can be completely elucidated. Without such studies, speculation of cell-specific roles in skin cancer promotion and progression, both for COX-2-dependent prostanoid production and for responses to COX-2-dependent prostanoid cell stimulation, cannot be tested and either validated or refuted. Moreover, this argument for necessity of cell-specific inactivation of critical genes can be generalized to most considerations of cell-cell interactions in complex microenvironments, if either more than one cell type expresses the signaling molecule in question or if more than one cell type expresses a capacity to respond to the signal.
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